 "Jubilant Life gets USFDA nod for generic anti-depressant")
Shares of Jubilant Life Sciences hit a four-month low of Rs 689 apiece on BSE, down 5 per cent in the intra-day trade on Tuesday. The stock of the pharmaceutical company was trading at its lowest level since November 21, 2018. It has fallen 21 per cent in five days.
On March 21, 2019, Jubilant Life Sciences said the United States Food and Drug Administration (USFDA) classified API manufacturing facility, in Nanjangud, Mysore, as Official Action Indicated (OAI).
USFDA also stated that the facility might be subject to a cGMP regulatory or enforcement action based on this inspection
On March 21, 2019, Jubilant Life Sciences said the United States Food and Drug Administration (USFDA) classified API manufacturing facility, in Nanjangud, Mysore, as Official Action Indicated (OAI).
USFDA also stated that the facility might be subject to a cGMP regulatory or enforcement action based on this inspection
